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Abstract
Background: Glypican-3 (GPC3) is a membrane-bound heparan sulfate proteoglycan that functions in embryonic
cell growth and differentiation and is highly expressed in the placenta. GPC3 is mutated in Simpson-Golabi-Behmel
syndrome, which is characterized by tissue overgrowth and an increased risk of embryonal malignancies. GPC3 has
also been implicated in sporadic cancer, particularly hepatocellular carcinoma, for which it has been shown to be a
useful diagnostic marker. Although GPC3 expression has been studied in non-neoplastic placental tissue, its
presence in gestational trophoblastic diseases has not been previously explored. The purpose of this study was to
investigate the immunohistochemical expression of GPC3 in placental site trophoblastic tumor (PSTT), a very rare
gestational trophoblastic neoplasm which may be morphologically confused with non-trophoblastic tumors, and to
assess its possible utility as a diagnostic marker.
Methods: Fifteen cases of PSTT, as well as samples from placental site nodule (PSN) (n = 2), leiomyosarcoma
(n = 1), leiomyoma (n = 1), invasive cervical squamous cell carcinoma (n = 7) and endometrial adenocarcinoma
(n = 11) were examined. Immunoreactivity was semi-quantitatively evaluated as negative (0, <5% of cells stained),
focally positive (1+, 5-10% of cells stained), positive (2+, 11-50% of cells stained) or diffusely positive (3+, >50% of
cells stained). Staining intensity for each subtype was graded from 0 to 3 and a mean intensity was calculated.
Results: Eighty percent of PSTT (12/15) were immunoreactive for GPC3 (0, 20; 1+, 20%; 2+, 40%; 3+, 20%) with a
mean intensity of 1.3. Stronger, predominately cytoplasmic staining was seen in larger multi- and mononucleated
cells with smaller mononucleate cells showing weak muddy cytoplasmic staining. Both PSN cases were positive
(1+, 50%; 2+, 50%) and two of nine invasive cervical squamous cell carcinomas showed staining (0, 57%; 1+, 29%;
2+, 14%), predominately in a basal distribution. Other uterine tumors and non-neoplastic tissues were negative.
Conclusions: Identification of GPC3 in PSTT and PSN is consistent with the derivation of these lesions from
intermediate trophoblasts, which have been described to express GPC3. GPC3 may be a useful adjunct
immunohistochemical marker in differentiating PSTT from non-trophoblastic tumors.
Background
Glypicans are a family of heparan sulfate proteoglycans
that are localized and anchored to the cell membrane
surface by a glycosylphosphatidylinositol anchor [1-3].
Like all heparan sulfate proteoglycans, glypicans consist
of a core protein, to which are attached two heparan
sulfate glycosaminoglycan polysaccharide chains. The
variability within these chains determines binding
specificity with different ligands, such as growth factors
and chemokines, which triggers intracellular signaling
pathways [1-3]. Ligands have also been shown to inter-
act with the core protein itself [4].
Glypican 3 (GPC3) is found in fetal tissues, but expres-
sion in adults is limited [5]. Experimental evidence using
cell cultures suggests that silencing occurs in tumors
derived from adult tissues which may normally express
GPC3 (ovary, breast, lung, and mesothelium), and has
therefore been considered to function as a tumor sup-
pressor in these tissues although this notion is controver-
sial [6-9]. In tissues with no adult expression, GPC3 may
act as an oncofetal protein, and tumors derived from
these tissues have increased levels of GPC3 mRNA (hepa-
tocellular carcinoma, hepatoblastoma, Wilms tumor,
neuroblastoma, and rhabdomyosarcoma), with protein
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glypicans in malignant transformation and tumor pro-
gression has been further elucidated by genetic studies
involving Drosophila and mice, which have shown that
the activity of Wnts, Hedgehogs, and bone morphoge-
netic proteins are modulated by glypicans [1-4,14]. GPC3
in particular has been shown to increase Wnt signaling
in hepatocellular carcinoma via interaction between Wnt
and GPC3 core protein [4].
Placental site trophoblastic tumor (PSTT), is a rare
form of gestational trophoblastic neoplasia (GTN), aris-
ing from an abnormal proliferation of intermediate tro-
phoblasts at the implantation site of the placenta, with
the potential for local invasion and metastases [15].
Morphologically, PSTT can be confused with other non-
trophoblastic neoplasms such as squamous cell carci-
noma (SCC). Expression studies suggest the presence of
a common trophoblastic stem cell (likely cytotropho-
blast) that undergoes subsequent neoplastic transforma-
tion into choriocarcinoma, and further differentiation of
PSTT and epithelioid trophoblastic tumor (ETT)
towards implantation site and chorionic-type intermedi-
ate trophoblastic cells respectively [15-17]. Identification
of these tumor subtypes as well as their differentiation
from non-trophoblastic tumors is important clinically
because the therapeutic approaches towards these dis-
eases differ. Gestational choriocarcinoma is highly sensi-
tive to chemotherapy, whereas PSTT and ETT are
refractory to chemotherapy and usually require surgical
resection or hysterectomy [16,17]. However, recognizing
the GTN subtypes and differentiating them from other
tumors can sometimes be challenging.
A prior study has shown that GPC3 is expressed by
normal human placental tissue–minimally by the undif-
ferentiated cytotrophoblast but markedly increased with
differentiation towards the syncytiotrophoblast–leading
to the belief that GPC3 expression is coupled to cell dif-
ferentiation and may play an important role in placental
growth and development [18]. Other recent studies have
shown that GPC3 is an immunohistochemical marker for
testicular and ovarian germ cell tumors, specifically yolk
sac tumor and choriocarcinoma [19-21]. No prior studies
have been done to investigate the expression of GPC3 in
gestational choriocarcinoma, PSTT, or ETT. The aim of
this study was to investigate the expression of GPC3 in
PSTT by immunohistochemistry to evaluate its potential
as an additional diagnostic marker for this tumor.
Methods
Archived (formalin-fixed, paraffin-embedded) tissue
blocks from 15 patients with PSTT were obtained
from the surgical pathology files of Northwestern
Memorial Hospital (5) and Yale New Haven Medical
Center (10). PSTT tumors were defined as tumors
with atypical medium to large sized mono- and multi-
nucleated cells that permeated through the myome-
trium. Out of the total 15 cases, 12 were uterine
primary tumors and 3 involved metastasis to the lungs.
Tissue from 11 endometrial adenocarcinoma cases, 7
invasive cervical SCC, 2 placental site nodules (PSN), 1
uterine leiomyosarcoma and 1 uterine leiomyoma were
also obtained for comparison.
Sections (5 um) from one representative block from
each case were deparaffinized, rehydrated in graded
alcohols, and subjected to heat-induced epitope retrieval
in 0.1 M citrate buffer at pH 6.0 in a microwave for 20
minutes. The slides were then incubated with a primary
monoclonal antibody specific for GPC3 (Biomosaics,
Burlington, VT) with a dilution of 1:200 for 1 hour at
room temperature. After incubation with rabbit anti-
mouse secondary antibody, a subsequent reaction was
performed with biotin-free HRP enzyme labeled polymer
of EnVision plus detection system (Dako Corporation,
Carpinteria, CA). 3,3’-diaminobenzidine was used as the
chromogen (Dako) and the sections were counterstained
with hematoxylin.
Each case was analyzed for cytoplasmic and membra-
nous staining. Immunoreactivity was semi-quantitatively
evaluated as negative (0, <5% of cells stained), focally
positive (1+, 5-10% of cells stained), positive (2+, 11-
50% of cells stained), or diffusely positive (3+, >50% of
cells stained). Staining intensity for each subtype was
graded from 0 to 3 and a mean intensity was calculated.
Adjacent benign uterine, cervix or lung tissue was also
assessed for percent of cells stained as well as strength
of staining. Normal mature placental tissue was used as
a positive control.
Results
GPC3 immunohistochemical results are summarized in
Table 1. Out of fifteen PSTT cases, three were negative
for GPC3 staining (0, 20%). Of the remaining twelve
cases, three were focally positive (1+, 20%), six were
moderately positive (2+, 40%) and three were diffusely
positive (3+, 20%). Of the cases that had GPC3 expres-
sion, five exhibited weak staining intensity (1, 33%), six
exhibited moderate staining intensity (2, 40%), and one
exhibited strong staining intensity (3, 6.7%), with a
mean intensity of 1.3. Stronger, predominately cytoplas-
mic staining with focal membranous expression was
seen in larger multi- and mononucleated cells. Smaller
mononucleate cells demonstrated weak muddy cytoplas-
mic staining (Fig. 1A-D). Similar reactivity was seen in
primary and metastatic lesions with one of the lung
tumor nodules negative and the other two showing 2+
positivity.
Both cases of PSN were positive with weak cytoplasmic
staining seen in the intermediate trophoblasts (Fig. 1E-F).
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cytoplasmic positivity, predominately in a basal distribu-
tion. Uterine tumors including one leiomyosarcoma, one
leiomyoma and eleven endometrial adenocarcinomas
were negative for GPC3 (Fig. 1G-H). Non-neoplastic tis-
sue adjacent to the tumor included myometrium (n = 5),
endometrium (n = 6), cervix (n = 2) and alveolar lung tis-
sue (n = 3) all of which were negative for GPC3 with no
background staining seen (Fig. 1I-J). Mature placental
tissue used as a positive control demonstrated diffusely
positive GPC3 staining with strong intensity in the
syncytiotrophoblasts.
Discussion
There are currently six glypican family members (GPC1
to GPC6) that have been identified in mammals, and
two in Drosophila melanogaster [22]. Research of glypi-
cans has increased due to the discovery that mutations
of the gene encoding GPC3 results in a rare, X-linked
overgrowth and dysmorphic syndrome called Simpson-
Golabi-Behmel Syndrome (SGBS) [23]. The GPC3 gene
is localized to Xq26, and its product is thought to regu-
late cellular growth and embryonic cell differentiation
through interactions with morphogenic or growth fac-
tors such as Wnt5a, fibroblast growth factor 2, bone
morphogenetic protein 7, tissue factor pathway inhibitor
and hedgehog proteins [11,24-27]. A mutation in the
gene speculated to render GPC3 nonfunctional results
in the clinical phenotype of SGBS patients, which
includes numerous craniofacial, skeletal, and genitourin-
ary abnormalities [28,29]. In addition, patients with
SGBS are at increased risk for certain tumors, most fre-
quently hepatocellular carcinoma, hepatoblastoma and
Wilms tumor [28-30]. GPC3 has also been linked to
various sporadic tumors, particularly hepatocellular
carcinoma, for which it has been shown to be a useful
diagnostic marker helpful in differentiating hepatocellu-
lar carcinoma from non-neoplastic liver disease [31-33].
GPC3 is expressed by normal human placental tissue,
notably by the syncytiotrophoblast at term, and may play
an important role in placental growth and development
[18]. In addition, a prior study has proposed that GPC3
may act as an anchor for placental protein 5 (PP5)/tissue
factor pathway inhibitor-2 (TFPI-2) on placental villi, and
a decrease in GPC3 expression in patients with pree-
clampsia may explain the increased levels of PP5/TFPI-2
in the serum of these patients [34]. In testicular germ cell
tumors, choriocarcinoma was consistently positive for
GPC3 with strong staining in the malignant syncytiotro-
phoblast and weaker staining in the cytotrophoblast [19].
Within ovarian mixed germ cell tumors, choriocarcinoma
was found to be immunoreactive for GPC3, showing
strong membranous reactivity with an additional case of
endometrial choriocarcinoma in the same study demon-
strating similar immunoreactivity [35]. Although chorio-
carcinoma of the ovary is histologically identical to
primary gestational choriocarcinomas, previous studies
have not yet investigated the expression of GPC3 in GTN
(including gestational choriocarcinoma, PSTT and ETT)
or other trophoblastic lesions, such as exaggerated
placental site (EPS) and PSN.
Although PSTT is very rare (about 1-2% of tropho-
blastic tumors overall), differentiation of PSTT from
other types of GTN, non-neoplastic gestational tropho-
blastic disease and non-trophoblastic tumors is impor-
tant clinically due to differences in their therapeutic
approaches [36]. Specifically, PSTT is refractory to che-
motherapy and usually requires treatment that includes
surgical resection or hysterectomy [16,17]. Because
PSTT commonly presents with a low and variable con-
centration of hCG in serum, tumors that secrete low to
negligible hCG are clinical considerations. The histolo-
gic differential diagnosis of PSTT includes gestational
choriocarcinoma, ETT, PSN, EPS, and non-trophoblastic
tumors such as epithelioid leiomyosarcoma and poorly
differentiated carcinoma, such as squamous cell carci-
noma (SCC) of the cervix or endometrial adenocarci-
noma [16]. The histopathology of PSTT has been
distinctly described as a proliferation of implantation
site intermediate trophoblast cells, mostly mononuclear
with occasional multinucleated tumor cells. The cells
have marked nuclear atypia, and tend to form confluent
sheets while extensively invading the uterus in nests that
separate the myometrial fibers reminiscent of normal
implantation [16]. Unlike choriocarcinoma, which is
usually dimorphic, PSTT is monophasic [36]. However,
Table 1 Summary of GPC3 immunoreactivity
0 (<5%
cells stained)
1+ (5-10%
cells stained)
2+ (11-50%
cells stained)
3+ (>50%
cells stained)
Mean
Intensity
Placental site trophoblastic tumor (n = 15) 3 (20%) 3 (20%) 6 (40%) 3 (20%) 1.3
Placental site nodule (n = 2) 0 1 (50%) 1 (50%) 0 1.5
Cervical squamous cell carcinoma (n = 7) 4 (57%) 2 (29%) 1 (14%) 0 0.7
Endometrial adenocarcinoma (n = 11) 11 (100%) 0 0 0 0
Uterine leiomyoma (n = 1) 1 (100%) 0 0 0 0
Leiomyosarcoma (n = 1) 1 (100%) 0 0 0 0
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noprofiles between subtypes of GTN, as well as mixed
lesions, which can make a definitive diagnosis difficult
[37,38]. In addition, the small amount of tissue obtained
from biopsy or endometrial curettage may limit the
accuracy of the initial pathologic examination.
In our study, GPC3 was expressed in the majority (80%)
of PSTT cases with an overall weak mean staining inten-
sity. This expression is consistent with the expression of
GPC3 in cells with extra-embryonic differentiation includ-
ing strong expression in normal placenta as well as tumors
which recapitulate the phenotype of extra-embryonic
membranes (amnion, yolk sac, chorion, and allantois),
such as gonadal and extra-gonadal choriocarcinoma and
yolk sac tumor [18]. The weak staining intensity of GPC3
in PSTT is concordant with previous conclusions that
PSTT consists of implantation site intermediate tropho-
blastic cells that originate from transformed cytotropho-
blasts, which have been described to stain weakly for
GPC3 compared to the differentiated syncytiotrophoblast
[18]. On examination, the pattern of GPC3 in PSTT
appears similar but weaker than that seen in gonadal and
extra-gonadal choriocarcinoma, with stronger expression
mostly limited to larger/multinucleate cells and weaker
expression in smaller, mononucleate cells. This pattern is
also described for hCG staining in PSTT and could be due
to the greater level of differentiation of these larger cells
[38]. Other immunohistochemical markers have been
reported for PSTT to help discriminate PSTT and other
trophoblastic/non-trophoblastic diseases including hPL,
β-hCG, Mel-CAM, cytokeratin 18, HLA-G and p63
[39-41]. Each of these markers each have their own limita-
tions, due to the lack of specificity of some of these mar-
kers for the trophoblast alone, as well as their variable
expression in the different subtypes of trophoblast [37-41].
GPC3 represents an additional marker with good sensitiv-
ity to corroborate the placental lineage of PSTT.
There have been no studies of GPC3 in other types of
GTN or non-neoplastic placental lesions. Although pre-
vious studies have not looked specifically at GPC3
expression in gestational choriocarcinoma, one may pre-
dict that–like the results obtained from choriocarcinoma
of testicular and ovarian germ cell tumors–gestational
choriocarcinoma is expected to have similar strong reac-
tivity in malignant syncytiotrophoblastic cells [21,35].
Like PSTT, ETT consists of intermediate trophoblastic
cells derived from a common trophoblastic stem cell.
One could predict that ETT will stain for GPC3 in a
similar fashion to PSTT, and so GPC3 might not be
useful in distinguishing between the two. However,
because both tumors are treated in similar ways, differ-
entiation between the two may not be clinically crucial
[16,17]. The few cases of PSN tested in this study
showed weak staining for GPC3, as expected for a lesion
composed of intermediate trophoblastic cells. GPC3
does not appear to discriminate between PSTT and
PSN.
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Figure 1 GPC3 expression in PSTT and other uterine and
cervical lesions. A. H&E of PSTT showing large tumor cells mixed
with smaller mononucleate tumor cells (20×). B. GPC3 immunostain
of PSTT showing focal strong reactivity, particularly in large tumor
cells, surrounded by smaller tumor cells with weak pale staining
(20×). C. H&E depicting large pleomorphic tumor cells in PSTT, some
of which are multinucleate (60×). D. GPC3 immunostain of PSTT
with variable reactivity, ranging from intense to very weak. Larger
cells appear to have the strongest reactivity (60×). E. H&E of PSN
showing degenerated intermediate trophoblasts in a hyalinized
background (20×). F. GPC3 immunostain of PSN depicting weak
cytoplasmic reactivity (20×). G. H&E of endometrial adenocarcinoma
(40×). H. GPC3 immunostain of endometrial adenocarcinoma
showing no reactivity (40×) I. H&E of uninvolved, nonneoplastic
endometrium (20×). J. GPC3 immunostain showing no reactivity in
nonneoplastic endometrium (20×).
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mon to the uterus did not express GPC3. We did not
find expression of GPC3 in endometrial adenocarcinoma
similar to a prior report [33]. In our study, a minority of
cases of invasive cervical SCC had expression of GPC3.
The pattern of basal staining was quite different than
for PSTT and PSN and should allow for discrimination
between these entities. A previous study also found that
the majority of cervical SCC did not express GPC3
(15%) [42]. GPC3 expression was also low in non-cervi-
cal SCC (anus, 20%; esophagus, 8%; oral cavity, 10%;
skin, 2%; urinary bladder, 13%; vulva, 12%) [42]. GPC3
was not expressed in uterine leiomyosarcoma and leio-
myoma in the few cases we examined. Similarly Baum-
hoer et al tested a large number of leiomyosarcomas
and found low GPC3 expression [42]. GPC3 may be
useful as an additional immunohistochemical marker to
distinguish PSTT from non-trophoblastic tumors com-
mon to the uterus.
Recent studies have shown that GPC3 may act not
only as a histochemical marker, but also as a serum
marker for early detection of HCC with potential identi-
fication of patients who have high levels of GPC3 for
possible targeted therapy [43,44]. As serum levels of
hCG are variable in PSTT and GPC3 is found in the
majority of primary and metastatic cases of PSTT,
GPC3 could represent a new serum marker to aid in the
clinical diagnosis of primary lesions and in patient fol-
low-up for the detection of metastases. Additionally, it
has been shown that anti-GPC3 monoclonal antibodies
targeting the C-terminal 30-kDa fragment of GPC3 in
serum induces antibody-dependent cellular cytotoxicity
(ADCC) and/or complement-dependent cytotoxicity
(CDC) against GPC3-positive human HCC cells in cul-
ture [45]. With the increasing detection of GPC3 in var-
ious tumors other than HCC, now including PSTT,
extending this targeted therapy approach to other GPC3
positive tumors may be possible.
Conclusion
In conclusion, GPC3 was positive in 80% of PSTT, with
sensitivity comparable to previously described markers
for this tumor. GPC3 is a promising immunohistochem-
ical marker for assisting in the diagnosis of PSTT, and
may present a potential serum marker and therapeutic
target.
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